Drug Profile
Retaspimycin - Infinity Pharmaceuticals
Alternative Names: IPI-504; MEDI-561; Retaspimycin hydrochlorideLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Infinity Pharmaceuticals
- Developer Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Massachusetts General Hospital
- Class Antineoplastics; Benzoquinones; Macrocyclic lactams; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal stromal tumours; HER2 positive breast cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 01 Oct 2014 Infinity Pharmaceuticals completes a phase I/II trial in Non-small cell lung cancer with KRAS mutation (combination therapy, second-line therapy) in USA (NCT01427946)
- 01 Apr 2014 Infinity Pharmaceuticals completes a phase II trial in Non-small cell lung cancer in Taiwan, Russia, Romania, South Korea, Hungary and USA (NCT01362400)
- 25 Sep 2013 Discontinued - Phase-II for Non-small cell lung cancer in Hungary (IV)